Associated Professor at University Hospital Of Larissa, Greece
Dr. Konstantinos Tsapakidis is an Assistant Professor of Medical Oncology at the Faculty of Medicine, University of Thessaly, Greece. He holds a Ph.D. in Medical Oncology, awarded with distinction, for his research on the proteasome/NFκB signaling pathway in prostate cancer. A certified Medical Oncology Specialist, he also holds the European Certification in Medical Oncology from ESMO. Dr. Tsapakidis has extensive clinical experience, having served in various roles at the University Hospital of Larissa, including consultant and resident doctor. His research interests span cancer biology, immune-oncology, and the role of nutrition in gastrointestinal and pancreatic cancers. In addition to his clinical and research work, he is an active educator in postgraduate programs related to oncology and clinical nutrition.
Professional Profile
SCOPUS
ORCID
Summary of Suitability for Research for Best Scholar Award
Dr. Konstantinos Tsapakidis brings a rich blend of academic distinction and clinical excellence in the field of Medical Oncology. With dual degrees in Medicine and Biology, a Ph.D. earned with excellent distinction, and an ESMO European Certification in Medical Oncology, he demonstrates a sustained and rigorous commitment to oncology research and education.
Education
Dr. Konstantinos Tsapakidis holds an extensive academic background in the medical sciences. He earned his Ph.D. in Medical Oncology from the University of Thessaly, School of Health Sciences, Faculty of Medicine in Larissa, Greece, in 2012, graduating with distinction. His doctoral research focused on exploring the relationship between cell-cycle regulators and apoptosis with the proteasome/NFκB system in prostate cancer. Prior to his doctorate, he obtained his medical degree (M.D.) from the University of Thessaly in 2007. He also holds a Bachelor’s degree in Biology from the Aristotle University of Thessaloniki, completed in 2002. Dr. Tsapakidis was awarded the title of Medical Oncology Specialist in March 2017 after successfully completing exams at the Faculty of Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki. Further enhancing his qualifications, he received the European Certification in Medical Oncology from the European Society for Medical Oncology (ESMO) in Munich in October 2018, along with 50 Category 1 ESMO-MORA points.
Experience
Dr. Konstantinos Tsapakidis has accumulated significant clinical and academic experience in the field of medical oncology. He currently serves as an Assistant Professor of Medical Oncology at the Faculty of Medicine, School of Health Sciences, University of Thessaly, a position he assumed in February 2025. Prior to this, he worked as a Consultant in Medical Oncology at the University Hospital of Larissa. His earlier roles at the same hospital include serving as a University Scholar and a Fellow with consultant responsibilities in the Department of Medical Oncology. Dr. Tsapakidis completed a residency in Medical Oncology at the University Hospital of Larissa, where he also engaged in volunteer evening clinical practice. His foundational training includes residencies in Internal Medicine at the General Hospital of Larissa and a six-month rotation in Hematology at the University Hospital of Larissa. He began his medical career as a Scientific Associate in the Department of Medical Oncology at the University Hospital of Larissa, serving from 2008 to 2009. Alongside his clinical work, he has contributed extensively to medical education, teaching postgraduate courses on the role of nutrition in gastrointestinal cancers and pancreatic cancer, and participating in thesis evaluation and academic mentoring over the past decade.
Research Interests
Dr. Konstantinos Tsapakidis focuses his research on the molecular mechanisms and therapeutic approaches in medical oncology, with particular emphasis on gastrointestinal and genitourinary cancers. His primary scientific interests include the role of cell-cycle regulators, apoptosis pathways, and the proteasome/NFκB signaling system in cancer progression, as explored in his doctoral work on prostate cancer. He is also deeply engaged in investigating the clinical application of immune-oncology and targeted therapies. Additionally, Dr. Tsapakidis has a strong interest in the relationship between nutrition and cancer development, especially in the context of esophageal, gastric, and pancreatic malignancies. His academic contributions reflect a multidisciplinary approach that integrates molecular oncology, clinical treatment strategies, and supportive care, including nutritional interventions for cancer patients undergoing chemotherapy and radiotherapy.
Awards & Certifications
Dr. Konstantinos Tsapakidis has been recognized for his academic and professional excellence through several awards and certifications. He was awarded the European Certification in Medical Oncology by the European Society for Medical Oncology (ESMO) in October 2018, held in Munich, which also included 50 Category 1 ESMO-MORA points—an acknowledgment of his advanced clinical knowledge and commitment to ongoing professional development in oncology. In March 2017, he earned the official specialist title in Medical Oncology after successfully passing national board examinations at the Department of Medical Oncology, Faculty of Medicine, Papageorgiou Hospital, Aristotle University of Thessaloniki. Additionally, he completed a certified e-learning program in Immune-Oncology from the University of Piraeus in 2017, further demonstrating his engagement with innovative cancer treatment approaches. His Ph.D., awarded with distinction by the University of Thessaly, also reflects his strong research capabilities and contribution to the understanding of cancer biology.
Top Noted Publications
Real-world data on immune checkpoint inhibitors in advanced sarcomas across multiple European institutions
Pseudomyxoma Peritonei: A Challenging Clinical Diagnosis. Case Report and Review of the Literature
The Impact of Expert Pathology Review and Molecular Diagnostics on the Management of Sarcoma Patients: A Prospective Study of the Hellenic Group of Sarcomas and Rare Cancers
Pre-Existing Immunity Predicts Response to First-Line Immunotherapy in Non-Small Cell Lung Cancer Patients
ES-SCLC Patients with PD-L1+ CTCs and High Percentages of CD8+PD-1+T Cells in Circulation Benefit from Front-Line Immunotherapy Treatment